The Leeds Bionanotechnology Group, School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK.
Department of Pathology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia.
Sci Rep. 2021 Jan 12;11(1):744. doi: 10.1038/s41598-020-80354-6.
Carcinoembryonic antigen (CEA) is the only blood based protein biomarker at present, used for preoperative screening of advanced colorectal cancer (CRC) patients to determine the appropriate curative treatments and post-surveillance screening for tumour recurrence. Current diagnostics for CRC detection have several limitations and development of a highly sensitive, specific and rapid diagnostic device is required. The majority of such devices developed to date are antibody-based and suffer from shortcomings including multimeric binding, cost and difficulties in mass production. To circumvent antibody-derived limitations, the present study focused on the development of Affimer proteins as a novel alternative binding reagent for CEA detection. Here, we describe the selection, from a phage display library, of Affimers specific to CEA protein. Characterization of three anti-CEA Affimers reveal that these bind specifically and selectively to protein epitopes of CEA from cell culture lysate and on fixed cells. Kinetic binding analysis by SPR show that the Affimers bind to CEA with high affinity and within the nM range. Therefore, they have substantial potential for used as novel affinity reagents in diagnostic imaging, targeted CRC therapy, affinity purification and biosensor applications.
癌胚抗原(CEA)是目前唯一用于术前筛选晚期结直肠癌(CRC)患者的基于血液的蛋白生物标志物,以确定适当的治疗方法,并进行肿瘤复发的术后监测。目前 CRC 的诊断方法存在一些局限性,因此需要开发一种高灵敏度、特异性和快速的诊断设备。迄今为止开发的大多数此类设备都是基于抗体的,存在多聚体结合、成本高和大规模生产困难等缺点。为了规避抗体衍生的局限性,本研究专注于开发适体蛋白作为 CEA 检测的新型替代结合试剂。在这里,我们描述了从噬菌体展示文库中选择针对 CEA 蛋白的适体。对三个抗 CEA 适体的表征表明,它们特异性地结合细胞培养裂解物和固定细胞中 CEA 的蛋白表位。SPR 的动力学结合分析表明,适体与 CEA 具有高亲和力,在纳摩尔范围内。因此,它们具有作为新型亲和试剂在诊断成像、靶向 CRC 治疗、亲和纯化和生物传感器应用中的巨大潜力。